Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 by Turck, D et al.
SCIENTIFIC OPINION
ADOPTED: 14 March 2019
doi: 10.2903/j.efsa.2019.5656
Nutrimune and immune defence against pathogens in the
gastrointestinal and upper respiratory tracts: evaluation of
a health claim pursuant to Article 14 of Regulation (EC)
No 1924/2006
EFSA Panel on Nutrition, Novel Foods and Food Allergens (EFSA NDA Panel),
Dominique Turck, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-Ernst,
John Kearney, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle,
Androniki Naska, Carmen Pelaez, Kristina Pentieva, Frank Thies, Sophia Tsabouri,
Marco Vinceti, Jean-Louis Bresson and Alfonso Siani
Abstract
Following an application from H.J. Heinz Supply Chain Europe B.V. submitted for authorisation of a
health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of
the Netherlands, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to
deliver an opinion on the scientiﬁc substantiation of a health claim related to Nutrimune and immune
defence against pathogens in the gastrointestinal (GI) tract and upper respiratory tract (URT). The
food Nutrimune (a pasteurised cow’s skim milk fermented with Lactobacillus paracasei CBA L74) which
is the subject of the health claim is sufﬁciently characterised. The Panel considers that immune
defence against pathogens in GI tract and URT is a beneﬁcial physiological effect. Two human
intervention studies were submitted as being pertinent to the claim, which were evaluated by the
Panel in the previous application. One human intervention study from which conclusions could be
drawn showed an effect of Nutrimune on immune defence against pathogens in the GI tract and the
URT. The post hoc re-analysis of the two human studies combined does not address the
methodological limitations of the second study raised in the previous opinion, i.e. that the study was
not planned, designed, randomised and analysed as a multicentre study, and that the large disparity of
subjects in the three centres was not duly justiﬁed. The results from one animal study could support
an effect of Nutrimune on defence against pathogens in the GI tract. No evidence was provided for a
plausible mechanism by which Nutrimune could exert the claimed effect in vivo in humans. The
Panel concludes that the evidence provided is insufﬁcient to establish a cause and effect relationship
between the consumption of Nutrimune and immune defence against pathogens in the GI tract and
URT.
© 2019 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
Keywords: Nutrimune, defence against pathogens, gastrointestinal tract, upper respiratory tract,
infection, children, health claim
Requestor: Competent Authority of the Netherlands following an application by H.J. Heinz Supply
Chain Europe B.V.
Question number: EFSA-Q-2018-00727
Correspondence: nda@efsa.europa.eu
EFSA Journal 2019;17(4):5656www.efsa.europa.eu/efsajournal
Panel members: Dominique Turck, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-
Ernst, John Kearney, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle,
Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco
Vinceti.
Acknowledgements: The Panel wishes to thank the members of the Working Group on Claims:
Jean-Louis Bresson, Stefaan de Henauw, Alfonso Siani and Frank Thies, for the preparatory work on
this scientiﬁc output.
Competing interests: A waiver was granted to Jean-Louis Bresson in accordance with Article 21 of
the Decision of the Executive Director on Competing Interest Management. Pursuant to Article 21(6) of
the afore-mentioned Decision, the concerned expert was allowed to take part in the discussion and in
the drafting phase of the scientiﬁc output.
Suggested citation: EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens),
Turck D, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Kearney J, Knutsen HK, Maciuk A, Mangelsdorf
I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Thies F, Tsabouri S, Vinceti M, Bresson J-L and Siani A,
2019. Scientiﬁc Opinion on Nutrimune and immune defence against pathogens in the gastrointestinal
and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC)
No 1924/2006. EFSA Journal 2019;17(4):5656, 12 pp. https://doi.org/10.2903/j.efsa.2019.5656
ISSN: 1831-4732
© 2019 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited and no
modiﬁcations or adaptations are made.
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2019;17(4):5656
Summary
Following an application from H.J. Heinz Supply Chain Europe B.V., submitted for authorisation of a
health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of
the Netherlands, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to
deliver an opinion on the scientiﬁc substantiation of a health claim related to Nutrimune and immune
defence against pathogens in the gastrointestinal (GI) tract and upper respiratory tract (URT).
The scope of the application was proposed to fall under a health claim referring to children’s
development and health.
The general approach of the NDA Panel for the evaluation of health claims applications is outlined
in the EFSA general guidance for stakeholders on health claim applications and the guidance on the
scientiﬁc requirements for health claims related to the immune system, the GI tract and defence
against pathogenic microorganisms.
The food proposed by the applicant as the subject of the health claim is Nutrimune. The
Panel considers that Nutrimune (a pasteurised cow’s skim milk fermented with Lactobacillus paracasei
CBA L74), which is the subject of the health claim, is sufﬁciently characterised.
The claimed effect proposed by the applicant is ‘supports the immune system in defence against
pathogens in the upper respiratory and gastrointestinal tract of young children’. The proposed target
population is ‘young children aged 12 – 48 months old’. The Panel considers that immune defence
against pathogens in the GI tract and URT is a beneﬁcial physiological effect.
In the present application, the applicant has submitted two human intervention studies as being
pertinent to the claim, which were evaluated by the Panel in the previous application (a one-centre
study and a multicentre study).
A number of textbooks/consensus opinions used for the diagnosis of upper respiratory tract
infection (URTI) and acute gastroenteritis were also provided. The Panel considers that the criteria
used for the diagnosis of URTI in the human intervention studies submitted have been further deﬁned
by the applicant.
The post hoc statistical re-analysis of the two human intervention studies provided has been
submitted. According to the applicant, the combined analysis aimed to: (a) increase the power of the
studies by assigning a positive event to the drop-outs, and (b) identify potential heterogeneity
between the two studies in order to address the multicentre approach in one of the studies.
The Panel notes that in the multicentre study, centre was found to be a signiﬁcant confounder for
the effect of Nutrimune on the incidence of infections, and that this effect was attributed to two
centres. The Panel also notes that tests for heterogeneity involving a small number of studies (or
centres) are likely to be underpowered, and therefore, non-signiﬁcant p values are not necessarily a
proof of non-heterogeneity. The Panel considers that the post hoc re-analysis of the two human
intervention studies combined does not address the methodological limitations of the multicentre study
raised by the Panel in its previous opinion, i.e. that the study was not planned, designed, randomised
and analysed as a multicentre study (as acknowledged by the applicant), and that the large disparity
of subjects recruited in the three centres was not duly justiﬁed.
As in the previous assessment, the Panel considers that the one-centre study shows an effect of
Nutrimune on immune defence against pathogens in the GI tract and the URT, whereas no conclusions
can be drawn from the multicentre study due to the high risk of bias.
As in the previous assessment, the Panel considers that the results from the animal study may
support an effect of Nutrimune on defence against pathogens in the GI tract, albeit the effects shown
are small, and found in a model that is very different from infections in humans.
As in the previous assessment, the Panel considers that no evidence has been provided for a
plausible mechanism by which Nutrimune could exert the claimed effect in vivo in humans.
In weighing the evidence, the Panel took into account that one human intervention study from
which conclusions could be drawn showed an effect of Nutrimune on immune defence against
pathogens in the GI tract and the URT, and that the results from one animal study could support an
effect of Nutrimune on defence against pathogens in the GI tract. The Panel also took into account
that the results of this study have not been replicated, and that no evidence was provided for a
plausible mechanism by which Nutrimune could exert the claimed effect in vivo in humans.
On the basis of the data provided, the Panel concludes that the evidence provided is insufﬁcient to
establish a cause and effect relationship between the consumption of Nutrimune and immune defence
against pathogens in the GI tract and URT.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a rule,
health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of authorised
claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this Regulation lay
down provisions for the authorisation and subsequent inclusion of reduction of disease risk claims and
claims referring to children’s development and health in a Community list of permitted claims.
According to this Regulation, an application shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientiﬁc substantiation of a health claim related to: Nutrimune and immune defence
against pathogens in the gastrointestinal and upper respiratory tracts.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of Nutrimune, a positive assessment of its safety, nor a decision on whether Nutrimune is,
or is not, classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
Information provided by the applicant
Food/constituent as stated by the applicant
According to the applicant, the food for which the health claim is made is ‘Nutrimune, a heat-
treated fermented milk product. It is fermented with Lactobacillus paracasei CBA L74’.
Health relationship as claimed by the applicant
According to the applicant, the claimed effect relates to: ‘supports the immune defence against
pathogens in the upper respiratory- and gastrointestinal tract’.
Mechanism by which the food/constituent could exert the claimed effect as proposed by
the applicant
The applicant claims that ‘claimed effects elicited by Nutrimune are mediated by a number of non-
immune and immune defence mechanisms. Nutrimune acts: through direct interaction with human
enterocytes regulating the innate immune response and modulating cell growth and differentiation,
intestinal permeability and mucus thickness, all well-known non-immune defence mechanisms against
infections. Indirectly through the gut microbiota, shaping and increasing the abundance of healthy gut
bacteria able to produce the short chain fatty acid butyrate, which in turn is responsible for a further
modulation of immune and non-immune defence mechanisms against infectious disease’.
Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘Nutrimune supports the
immune system in defence against pathogens in the upper respiratory and gastrointestinal tract of
young children’.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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Speciﬁc conditions of use as proposed by the applicant
According to the applicant, the target population for the intended health claim is ‘young children
aged 12 – 48 months old’. The applicant stated that ‘in the human trials doses of 7 gram of
Nutrimune, in spray-dried form, have been consumed daily for a period of 3 months by the target
group. This quantity of Nutrimune can be obtained through consumption of a range of products to
which Nutrimune can be added to. It is anticipated to apply Nutrimune in a range of products, in line
with existing legal/regulatory requirements and dietary consumption patterns for the target group’.
Data provided by the applicant
Health claim application on Nutrimune and immune defence against pathogens in the
gastrointestinal (GI) tract and upper respiratory tract (URT) pursuant to Article 14 of Regulation 1924/
2006, presented in a common and structured format as outlined in the Scientiﬁc and technical
guidance for the preparation and presentation of applications for authorisation of health claims.2
As outlined in the General guidance for stakeholders on health claim applications,3 it is the
responsibility of the applicant to provide the totality of the available evidence.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claims applications is outlined in
the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016a).
The scientiﬁc requirements for health claims related to the immune system, the GI tract and defence
against pathogenic microorganisms are outlined in a speciﬁc EFSA guidance (EFSA NDA Panel, 2016b).
The application contains data claimed as conﬁdential: International Depository Access Number, the
primers sequence, the melting temperature, the ampliﬁcation thermal cycle and the manufacturing
process.
The application contains data claimed as proprietary: International Depository Access Number,
primers sequence, the melting temperature and the ampliﬁcation thermal cycle.
3. Assessment
3.1. Characterisation of the food/constituent
The food proposed by the applicant as the subject of the health claim is Nutrimune.
Nutrimune is cow’s skim milk fermented with Lactobacillus paracasei CBA L74. Fermentation is
followed by pasteurisation to kill viable bacteria. The ﬁnal product is available as a spray-dried milk
powder containing at least 7 9 1010 colony forming units (CFU) of non-viable L. paracasei CBA L74 per
100 g of the product. It is anticipated that Nutrimune will be used as an ingredient in liquid, semi-
liquid and dry form in a variety of food products.
L. paracasei CBA L74 has been deposited in the internationally recognised Belgian collection
BCCM/LMG.
The species was identiﬁed using repetitive extragenic palindromic polymerase chain reaction (rep–PCR)
and a speciﬁc PCR. A single primer ﬁngerprinting technique was used to identify the strain. 16S rRNA and
23S rRNA gene sequence analysis were performed conﬁrming the identiﬁcation of the bacterial strain.
Detailed speciﬁcations of the manufacturing process, nutritional composition of the ﬁnal product,
and information on stability (all claimed as conﬁdential), were provided by the applicant.
The Panel considers that the food Nutrimune (a pasteurised cow’s skim milk fermented with
Lactobacillus paracasei CBA L74), which is the subject of the health claim, is sufﬁciently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘supports the immune defence against pathogens in
the upper respiratory- and gastrointestinal tract’. The proposed target population is ‘young children
aged 12–48 months old’.
2 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientiﬁc and technical guidance for the preparation and
presentation of an application for authorisation of a health claim (revision 1). EFSA Journal 2011;9(5):2170, 36 pp. https://
doi.org/10.2903/j.efsa.2011.2170
3 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016. General scientiﬁc guidance for stakeholders
on health claim applications. EFSA Journal 2016;14(1):4367, 38 pp. https://doi.org/10.2903/j.efsa.2016.4367
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As explained in the Guidance on the scientiﬁc requirements for health claims related to the immune
system, the GI tract and defence against pathogenic microorganisms (EFSA NDA Panel, 2016b), the
scientiﬁc evidence for the substantiation of health claims related to defence against pathogens in the
upper respiratory tract (URT) can be obtained from human intervention studies showing an effect on
clinical outcomes related to infections (e.g. incidence, severity and/or duration of symptoms) of the
upper respiratory tract (e.g. rhinitis, pharyngitis, sinusitis, otitis media, common cold). Upper
respiratory tract infections (URTI) clinically diagnosed by the primary care or hospital physician
following well deﬁned criteria can be used as an appropriate outcome variable for the scientiﬁc
substantiation of the claim, provided that adequate exclusion criteria for the most common non-
infectious causes (e.g. allergic diseases) of the signs and symptoms used for diagnosis of the URTI
have been applied (i.e. differential diagnosis). Microbiological data could also be used to ascertain the
infectious aetiology of clinically diagnosed episodes.
For health claims related to defence against pathogens in the GI tract, clinical outcomes related to
GI infections, for example incidence, severity and/or duration of diarrhoeal episodes could be used.
The infectious aetiology of diarrhoeal episodes, however, should be ascertained. In this context, GI
infection clinically diagnosed by the primary care or hospital physician following well-deﬁned criteria
can be used as an appropriate outcome variable for the scientiﬁc substantiation of the claim, provided
that adequate exclusion criteria for the most common non-infectious causes of diarrhoea have been
applied. Microbiological data could also be used to ascertain the infectious aetiology of diarrhoeal
episodes.
Other outcome variables, such as changes in relevant immunological markers, may provide
supportive evidence on the mechanism (e.g. through the activation of the immune system) by which
the food/constituent could exert the claimed effect, but alone are not appropriate for the
substantiation of claims related to immune defence against pathogens.
The Panel considers that immune defence against pathogens in the GI tract and URT is a beneﬁcial
physiological effect.
3.3. Scientiﬁc substantiation of the claimed effect
In 2016, the Panel assessed a claim on ‘Nutrimune’ and ‘immune defence against pathogens in the
gastrointestinal and upper respiratory tracts’ pursuant to Article 14 of Regulation (EC) No 1924/2006
(EFSA NDA Panel, 2017).
At that time, the applicant provided two human intervention studies (Nocerino, 2013; unpublished
study report; Corsello et al., 2015, unpublished study report) as being pertinent to the claim. The
applicant also provided one animal efﬁcacy study (Zagato et al., 2014), as well as in vitro studies
(Sarno et al., 2013, abstract; Paparo et al., 2014, abstract) in support of the mechanisms by which
Nutrimune could exert the claimed effect.
The Panel considered that the study by Corsello et al., 2015 (unpublished study report) was at high
risk of bias and that no conclusions could be drawn for the scientiﬁc substantiation of the claim.
In weighing the evidence, the Panel took into account that one human intervention study from
which conclusions could be drawn showed an effect of Nutrimune on immune defence against
pathogens in the GI tract and the URT (Nocerino, 2013, unpublished study report), and that the
results from one animal study could support an effect of’ Nutrimune on defence against pathogens in
the GI tract (Zagato et al., 2014). The Panel also took into account the inconsistencies in the reporting
of the process and criteria used for the diagnosis of URTI in the human intervention study, that the
results of this study have not been replicated, and that no evidence was provided for a plausible
mechanism by which Nutrimune could exert the claimed effect in vivo in humans.
The Panel concluded that the evidence provided was insufﬁcient to establish a cause and effect
relationship between the consumption of Nutrimune and immune defence against pathogens in the GI
tract and URT.
For the present application, the applicant has provided:
1) Three publications (Berni Canani et al., 2016; Corsello et al., 2017; Nocerino et al., 2017)
reporting on the two human intervention studies which were provided in the previous
application as unpublished study reports (Nocerino, 2013; Corsello et al., 2015). For
convenience, these studies will be quoted as Nocerino et al., 2017 and Corsello et al., 2017
in this opinion.
2) A statistical re-analysis (Calame, 2018, unpublished) of the two human intervention studies.
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3) Text books/consensus opinions used for the diagnosis of URTI and acute GI infections
(Guarino et al., 2008; Marchisio et al., 2010; Chiappini et al., 2012; Hersh et al., 2013;
Lieberthal et al., 2013).
4) One animal efﬁcacy study provided in the previous application (Zagato et al., 2014)
5) Three publications reporting on mechanistic studies (Sarno et al., 2014; Berni Canani et al.,
2017; Paparo et al., 2018), two of which (Sarno et al., 2014; Paparo et al., 2018) were
submitted in the previous application as abstracts only and could not be considered by the
Panel for a full scientiﬁc assessment.
Human intervention studies
The applicant has submitted two human intervention studies as being pertinent to the claim, which
were evaluated by the Panel in the previous application. The Panel concluded that Nocerino et al.
(2017) showed an effect of Nutrimune on immune defence against pathogens in the GI tract and the
URT. The Panel noted, however, inconsistencies in the reporting of the process and in the criteria used
for the diagnosis of URTI. In relation to the second study (Corsello et al., 2017), the Panel noted that
the vast majority of the participants were recruited in one centre (i.e. 105 in Naples, 17 in Milan, and
24 in Palermo), that the statistical analysis provided is not appropriate for the study data (i.e. the
same weight is given to all centres, regardless of their sample size), and that if the study was not
planned, designed, randomised and analysed as a multicentre study (as acknowledged by the
applicant), the aleatory recruitment of subjects in three different centres is not duly justiﬁed. The
Panel also noted that this study shared the same inconsistencies in the reporting of the process and
criteria used for the diagnosis of URTI as identiﬁed for the study by Nocerino et al. (2017). The
Panel considered that this study was at high risk of bias and that no conclusions could be drawn for
the scientiﬁc substantiation of the claim.
In the present application, a number of textbooks/consensus opinions used for the diagnosis of
URTI and acute gastroenteritis were provided (Guarino et al., 2008; Marchisio et al., 2010; Chiappini
et al., 2012; Hersh et al., 2013; Lieberthal et al., 2013). The Panel considers that the criteria used for
the diagnosis of URTI in the studies by Nocerino et al. (2017) and Corsello et al. (2017) have been
further deﬁned by the applicant.
The post hoc statistical re-analysis (Calame, 2018, unpublished) consists of a combined analysis
with data from one study (Nocerino et al., 2017) and data from each centre (n = 3) participating in
the second study (Corsello et al., 2017). According to the applicant, the combined analysis aimed to:
(a) increase the power of the studies by assigning a positive event to the drop-outs, and (b) identify
potential heterogeneity between the two studies in order to address the multicentre approach in the
study by Corsello et al. (2017).
In order to establish how the results from the two studies differ, heterogeneity was tested as
follows:
a) By meta-analysis on both studies using aggregated data and applying the random effects
model for GI infections, URTI and overall number of infections, for the intention to treat
(ITT) and per protocol (PP) populations. Heterogeneity between the two studies was
assessed using Chi-squared and I-squared. The same approach was followed when the
analysis was restricted to the Naples centre in both studies.
b) By a General Equations Estimation model used in a paired stepwise dummy fashion to assess
the effect of Nutrimune on the outcome while considering possible confounders, including
centre. This analysis was conducted in the PP population.
c) By a cumulative meta-analysis to assess the centre effect on the outcome and determine the
heterogeneity in the outcome between the various centres (ITT population). A stepwise
analysis per centre was followed starting with the centre with the lowest number of
participants. Heterogeneity was assessed using the Egger test.
The results of these analyses lead the applicant to the following conclusions:
a) No signiﬁcant heterogeneity was found between the results of two studies in any of the
meta-analysis performed.
b) Centre was found to be a signiﬁcant confounder related to the low power in the Milan and
Palermo centres in the study by Corsello et al. (2017).
c) No signiﬁcant heterogeneity was found among centres in the cumulative meta-analysis.
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The Panel notes that centre was found to be a signiﬁcant confounder for the effect of Nutrimune
on the incidence of infections, and that this effect was attributed to the Milan and Palermo centres in
the study by Corsello et al. (2017). The Panel also notes that tests for heterogeneity involving a small
number of studies (or centres) are likely to be underpowered, and therefore non-signiﬁcant p values
are not necessarily a proof of non-heterogeneity.
The Panel considers that the post hoc re-analysis of the two human intervention studies combined
does not address the methodological limitations of the study by Corsello et al. (2017) raised by the
Panel in its previous opinion, i.e. that the study was not planned, designed, randomised and analysed
as a multicentre study (as acknowledged by the applicant), and that the large disparity of subjects
recruited in the three centres was not duly justiﬁed.
As in the previous assessment (EFSA NDA Panel, 2017), the Panel considers that the study by
Nocerino et al. (2017) shows an effect of Nutrimune on immune defence against pathogens in the GI
tract and the URT, whereas no conclusions can be drawn from the study by Corsello et al. (2017) due
to the high risk of bias.
Animal efﬁcacy studies
The applicant provided one animal study for the scientiﬁc substantiation of the claim (the same as
in the previous application) (Zagato et al., 2014). Twenty mice were fed with Nutrimune or non-
fermented milk (control) for 10 days and then were challenged intragastrically with a lethal dose of
Salmonella typhimurium FB62 (106 CFU in 200 lL carbonate buffer). Mice receiving Nutrimune
survived slightly longer (statistically signiﬁcantly) than mice in the control group.
As in the previous assessment (EFSA NDA Panel, 2017), the Panel considers that the results from this
animal study may support an effect of Nutrimune on defence against pathogens in the GI tract, albeit the
effects shown are small, and found in a model that is very different from infections in humans.
Mechanism of action proposed
The applicant claims that ‘it has been demonstrated that Nutrimune modulates several non-immune
and immune defence mechanisms against pathogens’.
The application contains mechanistic studies provided already in the previous application and a
number of new studies. Most of them are presented as abstracts (Cuomo et al., 2013; Sarno et al.,
2013; Barone et al., 2014; Paparo et al., 2014, 2016). The limited information provided in these
abstracts does not allow the Panel to perform a full scientiﬁc evaluation.
Three new studies were submitted as full publications.
Paparo et al. (2018) incubated Caco-2 cells with Nutrimune at different concentrations for 48 h.
Nutrimune stimulated cell growth and differentiation, tight junction proteins, mucin 2 expression, and
mucus layer thickness in a dose-dependent fashion. Stimulation of beta-defensin-2 (hBD-2) and
cathelicidin synthesis, associated with a modulation of toll-like receptor (TLR) pathway, was also
observed. In the ex vivo study by Berni et al. (2017), the number of gut microbiota known as
butyrate-producers, such as Oscillospira and Faecalibacterium, were increased by Nutrimune. CBA L74
supernatant signiﬁcantly prevented the entrance of gliadin peptides and reduced reactive oxygen
species (ROS) production in human Caco-2 cells (Sarno et al., 2014). The Panel notes that no evidence
has been provided to establish a causal relationship between changes in the variables reported in
these studies and changes in the outcome variables for the claimed effect assessed in this application
(incidence, severity, duration of GT tract and URT infections in vivo in humans).
As in the previous assessment (EFSA NDA Panel, 2017), the Panel considers that no evidence has
been provided for a plausible mechanism by which Nutrimune could exert the claimed effect in vivo in
humans.
Weighing of the evidence
In weighing the evidence, the Panel took into account that one human intervention study from
which conclusions could be drawn showed an effect of Nutrimune on immune defence against
pathogens in the GI tract and the URT, and that the results from one animal study could support an
effect of Nutrimune on defence against pathogens in the GI tract. The Panel also took into account
that the results of the human study have not been replicated, and that no evidence was provided for a
plausible mechanism by which Nutrimune could exert the claimed effect in vivo in humans.
The Panel concludes that the evidence provided is insufﬁcient to establish a cause and effect
relationship between the consumption of Nutrimune and immune defence against pathogens in the
gastrointestinal and upper respiratory tracts.
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4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food/constituent, Nutrimune, which is the subject of the health claim, is sufﬁciently
characterised.
• The claimed effect proposed by the applicant is ‘supports the immune defence against
pathogens in the upper respiratory and gastrointestinal tract’. The target population proposed
by the applicant is ‘young children aged 12–48 months old’. Immune defence against
pathogens in the gastrointestinal and upper respiratory tracts is a beneﬁcial physiological
effect.
• The evidence provided is insufﬁcient to establish a cause and effect relationship between the
consumption of Nutrimune and immune defence against pathogens in the gastrointestinal and
upper respiratory tracts.
Steps taken by EFSA
Health claim application on “Nutrimune and immune defence against pathogens in the gastrointestinal
and upper respiratory tracts” pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No:
0480_NL). Submitted by Heinz Supply Chain Europe B.V., Nieuwe Dukenburgseweg 19, Nieuwe
Dukenburgseweg 19, The Netherlands.
1) This application was received by EFSA on 21/09/2018.
2) The scope of the application was proposed to fall under a health claim related to reduction
of disease risk claims and claims referring to children’s development.
3) The scientiﬁc evaluation procedure started on 26/11/2018.
4) On 28/11/2018, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was suspended on 13/12/2018 and was restarted on 9/01/2019, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
5) On 16/01/2019, the applicant’s hearing took place to give the opportunity to the applicant to
comment/clarify the issues identiﬁed by the Working Group on Claims.
6) During its meeting on 14/03/2019, the NDA Panel, having evaluated the data, adopted an
opinion on the scientiﬁc substantiation of a health claim related to Nutrimune and immune
defence against pathogens in the gastrointestinal and upper respiratory tracts.
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CFU colony forming units
GI gastrointestinal
hBD-2 human beta-defensin-2
ITT intention to treat
NDA EFSA Panel on Nutrition, Novel Foods and Food Allergens
PCR polymerase chain reaction
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PP per protocol
REP repetitive extragenic palindromic
RNA ribonucleic acid
ROS reactive oxygen species
TLR toll-like receptor
URT upper respiratory tract
URTI upper respiratory tract infection
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